The data from NASH-HCC mice suggested that aberrant FGF15/FGFR4 signaling and lipid metabolic disorder contributed to tumor-initiation for the carcinogenetic process. The gene discussed is FGFR4; the disease is metabolic dysfunction-associated steatohepatitis.